Rating of The Day: Toronto: Concordia Healthcare Corp (TSE:CXR)’s Stock Had Its Sector Perform Rating Restated at RBC Capital Markets in Report Issued Today. Has $3.50 Target

November 28, 2016 - By Peter Erickson

Concordia Healthcare Corp (TSE:CXR) Rating

In an analyst report revealed to investors on 28 November, Concordia Healthcare Corp (TSE:CXR) stock had its Sector Perform Rating reconfirmed by stock research analysts at RBC Capital Markets. They currently have a $3.50 PT on firm. RBC Capital Markets’s target means a potential downside of -1.96% from the company’s last price.

Concordia International Corp (TSE:CXR) Ratings Coverage

Out of 4 analysts covering Concordia Healthcare Corp (TSE:CXR), 0 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 0 are positive. $135 is the highest target while $2 is the lowest. The $28.40 average target is 695.52% above today’s ($3.57) stock price. Concordia Healthcare Corp has been the topic of 26 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Tuesday, June 7, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained the shares of CXR in a report on Tuesday, August 11 with “Outperform” rating. RBC Capital Markets maintained Concordia International Corp (TSE:CXR) rating on Monday, June 20. RBC Capital Markets has “Outperform” rating and $73 price target. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, October 24. The firm has “Outperform” rating given on Monday, October 17 by RBC Capital Markets. The stock has “Outperform” rating given by RBC Capital Markets on Monday, May 16. The rating was maintained by RBC Capital Markets on Tuesday, October 11 with “Outperform”. The stock of Concordia International Corp (TSE:CXR) earned “” rating by Goldman Sachs on Friday, July 22. The firm has “Outperform” rating by RBC Capital Markets given on Friday, January 8. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, October 31 report.

About 456,094 shares traded hands. Concordia International Corp (TSE:CXR) has declined 91.34% since April 22, 2016 and is downtrending. It has underperformed by 97.35% the S&P500.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada pharmaceutical company. The company has a market cap of $179.17 million. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. It currently has negative earnings.

CXR Company Profile

CSX Corporation, together with its subsidiaries, incorporated on November 15, 1978, is a transportation company. The Firm provides rail transportation services, including rail service and the transport of intermodal containers and trailers. The Firm serves approximately three lines of business, such as merchandise business, coal business and intermodal business. The Company’s operating subsidiary, CSX Transportation, Inc. (CSXT), provides a link to the transportation supply chain through its approximately 21,000-route mile rail network, which serves population centers in approximately 20 states east of the Mississippi River, the District of Columbia and the Canadian provinces of Ontario and Quebec. It has access to over 70 ocean, river and lake port terminals along the Atlantic and Gulf Coasts, the Mississippi River, the Great Lakes and the St. Lawrence Seaway. The Company’s intermodal business links clients to railroads through trucks and terminals. CSXT also serves production and distribution facilities through track connections to approximately 240 short-line and regional railroads.

More recent Concordia International Corp (TSE:CXR) news were published by: Prnewswire.com which released: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016. Also Prnewswire.com published the news titled: “Concordia International Corp. Announces Communication With CMA” on October 25, 2016. Prnewswire.com‘s news article titled: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” with publication date: August 17, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>